{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:01:49Z","timestamp":1784768509180,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"publisher","award":["IRC15-006"],"award-info":[{"award-number":["IRC15-006"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["IMI-2008\/115006"],"award-info":[{"award-number":["IMI-2008\/115006"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019434","name":"NIHR Exeter Clinical Research Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006189","name":"Direkt\u00f6r\u00a0Albert P\u00e5hlssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vph.2023.107214","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T20:49:23Z","timestamp":1692996563000},"page":"107214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk"],"prefix":"10.1016","volume":"152","author":[{"given":"Andreas","family":"Edsfeldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Vigren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Jovanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Engstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Natali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisel","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2023.107214_bb0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How common is residual inflammatory risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2023.107214_bb0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0015","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0020","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0025","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2023.107214_bb0030","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2020.08.052","article-title":"Targeting Interleukin-1 and Interleukin-6: The time has come to aggressively address residual inflammatory risk","volume":"76","author":"Ridker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2023.107214_bb0035","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-Interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2023.107214_bb0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.vph.2023.107214_bb0045","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","article-title":"The balance of interleukin (IL)-6, IL-6.Soluble IL-6 receptor (sIL-6R), and IL-6.sIL-6R.sgp130 complexes allows simultaneous classic and trans-signaling","volume":"293","author":"Baran","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2023.107214_bb0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/eji.1830230226","article-title":"The soluble interleukin-6 receptor is generated by shedding","volume":"23","author":"Mullberg","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.vph.2023.107214_bb0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/1043-4666(92)90043-Q","article-title":"Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor","volume":"4","author":"Lust","year":"1992","journal-title":"Cytokine"},{"key":"10.1016\/j.vph.2023.107214_bb0060","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.4049\/jimmunol.0901929","article-title":"Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor","volume":"184","author":"McFarland-Mancini","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.vph.2023.107214_bb0065","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic T(H)17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.vph.2023.107214_bb0070","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107214_bb0075","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.atherosclerosis.2015.04.014","article-title":"Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction","volume":"240","author":"Moreno Velasquez","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2023.107214_bb0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cvr\/cvy191","article-title":"Interleukin 6 trans-signalling and risk of future cardiovascular events","volume":"115","author":"Ziegler","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2023.107214_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2796.1993.tb00647.x","article-title":"The Malmo diet and Cancer study. Design and Feasibility","volume":"233","author":"Berglund","year":"1993","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1464-5491.2000.00280.x","article-title":"Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden","volume":"17","author":"Hedblad","year":"2000","journal-title":"Diabet. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/joim.12359","article-title":"Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study","volume":"278","author":"Shore","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0100","article-title":"Plaque characteristics and biomarkers predicting regression and progression of carotid atherosclerosis","volume":"3","author":"Khan","year":"2022","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0105","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1161\/01.STR.0000147038.12073.59","article-title":"Elastin and calcium rather than collagen or lipid content are associated with echogenicity of human carotid plaques","volume":"35","author":"Goncalves","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2023.107214_bb0110","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/ATVBAHA.114.303414","article-title":"Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes","volume":"34","author":"Edsfeldt","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2023.107214_bb0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009874","article-title":"High levels of soluble Lectinlike oxidized low-density lipoprotein Receptor-1 are associated with carotid plaque inflammation and increased risk of ischemic stroke","volume":"8","author":"Markstad","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2023.107214_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ebiom.2017.11.023","article-title":"Elevated markers of death receptor-activated apoptosis are associated with increased risk for development of diabetes and cardiovascular disease","volume":"26","author":"Mattisson","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vph.2023.107214_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8587","article-title":"Evidence for a protective role of placental growth factor in cardiovascular disease","volume":"12","author":"Chen","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0130","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, asprin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0135","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1161\/CIRCRESAHA.122.320877","article-title":"Interleukin-6 predicts carotid plaque severity, vulnerability, and progression","volume":"131","author":"Kamtchum-Tatuene","year":"2022","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2023.107214_bb0140","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1161\/01.HYP.0000185463.27209.b0","article-title":"Arterial stiffness is related to systemic inflammation in essential hypertension","volume":"46","author":"Mahmud","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2023.107214_bb0145","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2337\/dc06-1793","article-title":"Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity","volume":"30","author":"Esteve","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vph.2023.107214_bb0150","first-page":"337","article-title":"Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum","volume":"10","author":"Gaillard","year":"1999","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.vph.2023.107214_bb0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/art.20727","article-title":"Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells","volume":"52","author":"Franchimont","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2023.107214_bb0160","doi-asserted-by":"crossref","first-page":"38829","DOI":"10.1074\/jbc.M210584200","article-title":"Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)","volume":"278","author":"Matthews","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2023.107214_bb0165","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/07853890009011772","article-title":"Function of C-reactive protein","volume":"32","author":"Du Clos","year":"2000","journal-title":"Ann. Med."},{"key":"10.1016\/j.vph.2023.107214_bb0170","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/ATVBAHA.111.229435","article-title":"Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice","volume":"32","author":"Schuett","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2023.107214_bb0175","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2023.107214_bb0180","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Interleukin-6 Receptor Mendelian Randomisation Analysis, C","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2023.107214_bb0185","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/bcp.15191","article-title":"Dissecting the IL-6 pathway in cardiometabolic disease: a Mendelian randomization study on both IL6 and IL6R","volume":"88","author":"Cupido","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2023.107214_bb0190","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41577-019-0240-6","article-title":"Efferocytosis in health and disease","volume":"20","author":"Doran","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.vph.2023.107214_bb0195","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/01.ATV.19.10.2364","article-title":"Interleukin-6 exacerbates early atherosclerosis in mice","volume":"19","author":"Huber","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2023.107214_bb0200","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1161\/01.CIR.0000148135.08582.97","article-title":"Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis","volume":"110","author":"Schieffer","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107214_bb0205","doi-asserted-by":"crossref","first-page":"1396398","DOI":"10.1155\/2017\/1396398","article-title":"Interleukin-6 \u201ctrans-signaling\u201d and ischemic vascular disease: The important role of soluble gp130","volume":"2017","author":"Morieri","year":"2017","journal-title":"Mediat. Inflamm."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:23:09Z","timestamp":1761528189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189123000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":41,"alternative-id":["S1537189123000745"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2023.107214","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2023.107214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107214"}}